Key result
Prehospital thrombolysis for STEMI is cost-effective at ~$16,800 per QALY gained vs alternate care.
Why the study?
Although the clinical benefits of paramedic-administered prehospital thrombolysis for STEMI are proven, its cost-effectiveness remained to be established.
Does paramedic-administered prehospital thrombolysis improve cost-effectiveness (cost per QALY gained) in patients with prehospital STEMI compared to an alternate treatment pathway?
Does paramedic-administered prehospital thrombolysis improve cost-effectiveness (cost per QALY gained) in patients with prehospital STEMI compared to an alternate treatment pathway?
Paramedic-administered prehospital thrombolysis for STEMI in Queensland, Australia is cost-effective, costing AUD 16,750.22 (USD 11,725.15) per QALY gained over a lifetime horizon.
Answers are grounded in this paper and cite their sources.
Model supports EMS cost-effectiveness for STEMI thrombolysis; leaves open prospective validation before practice change.
Guidelines recommend prehospital thrombolysis for ST-segment elevation myocardial infarction (STEMI) if trained clinicians can interpret 12-lead electrocardiogram (ECG) on site. The Queensland Ambulance Service (QAS) has a well-established prehospital reperfusion program under which all paramedics are trained in prehospital STEMI diagnosis on 12-lead ECG and administering thrombolysis in the field to eligible patients. Whilst the clinical benefits of this treatment are proven, its cost-effectiveness remains to be established. We developed a decision-analytic microsimulation model to evaluate the cost-effectiveness of paramedic-administered thrombolysis for prehospital STEMI in the state of Queensland, Australia. The comparator was a hypothetical counterfactual group of patients who were clinically eligible for prehospital thrombolysis but received an alternate treatment pathway. The analysis was conducted from a health provider (Queensland Government) perspective. A lifetime time horizon was used. Input values of the acute phase were derived from our prehospital and linked hospital database of all STEMI patients receiving prehospital thrombolysis from QAS paramedics between January 2022 and December 2024. Input values of the long-term phase were obtained from published literature. Cost was expressed in Australian dollars (AUD) and United States dollars (USD) in 2026 value, and effectiveness in quality-adjusted life years (QALYs). Prehospital thrombolysis improved outcomes at a cost of AUD 16,750.22 per QALY gained (95% uncertainty range AUD 15,477.48 – 18,422.84) or USD 11,725.15 (USD 10,834.24 – 12,895.99). In the sensitivity analysis, the cost-effectiveness of prehospital thrombolysis was robust to changes in input values. Paramedic-administered thrombolysis in the field for prehospital STEMI, compared with no such treatment, represents value for money.
No takes yet. Share an insight, caveat, or question.
Doan et al. (2026) studied ST-segment elevation myocardial infarction (STEMI). Paramedic-administered prehospital thrombolysis vs. Hypothetical counterfactual group receiving an alternate treatment pathway without prehospital thrombolysis was evaluated on Incremental cost per quality-adjusted life year (QALY) gained (ICER AUD 16,750.22/QALY (USD 11,725.15/QALY), 95% CI AUD 15,477.48-18,422.84 (USD 10,834.24-12,895.99)). Paramedic-administered prehospital thrombolysis for STEMI was cost-effective vs alternate care at AUD 16,750.22/QALY gained.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: